Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Meijun Xiong, Qingsong Wu, Yanchun Li, Chong Liu, Yajun Sun, Zengyan Mu, Xinju Gao, Yanwen Feng, Haibo He, Paul H. Song, Gang Qin

Cancer Res (2025) 85 (8_Supplement_1): 5734.

https://doi.org/10.1158/1538-7445.AM2025-5734

Published: 21 April 2025

View articletitled, Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Journal Articles

Abstract 347: Novel EGFR x cMET bispecific ADC GQ1033 and DLL3-ADC GQ1030 demonstrated promising therapeutic efficacy in preclinical studies

Sipeng Li, Yajun Sun, Meijun Xiong, Chong Liu, Yanwen Feng, Zengyan Mu, Xinju Gao, Yu Han, Paul H. Song, Gang Qin

Cancer Res (2025) 85 (8_Supplement_1): 347.

https://doi.org/10.1158/1538-7445.AM2025-347

Published: 21 April 2025

View articletitled, Abstract 347: Novel EGFR x cMET bispecific ADC GQ1033 and DLL3-ADC GQ1030 demonstrated promising therapeutic efficacy in preclinical studies

Journal Articles

Abstract 4332: Concomitant therapy leveraging antibody-pan-KRAS^mt siRNA conjugate for PDAC and LUAD harboring KRAS mutations

Aiyun Wen, Jing Guo, Zengyan Mu, Chengang Zhou, Junhao Wang, Tongtong Hu, Haibo He, Meijun Xiong, Cong Liu, Paul H. Song, Gang Qin

Cancer Res (2025) 85 (8_Supplement_1): 4332.

https://doi.org/10.1158/1538-7445.AM2025-4332

Published: 21 April 2025

View articletitled, Abstract 4332: Concomitant therapy leveraging antibody-pan-KRASmt siRNA conjugate for PDAC and LUAD harboring KRAS mutations

Journal Articles

Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

Byeongkwi Min, Sunghyun Lee, Wonsik Jung, Lina Wang, Yajun Sun, Hyejin Kim, Nam-Gu Her, Paul H. Song, Gang Qin, Do-Hyun Nam

Cancer Res (2024) 84 (6_Supplement): 3123.

https://doi.org/10.1158/1538-7445.AM2024-3123

Published: 22 March 2024

View articletitled, Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

Journal Articles

Abstract 6032: A novel “add-on” nanobody with an albumin-binding moiety based on the intelligent ligase-dependent conjugation (iLDC) technology: An innovative and versatile approach for next-generation radionuclide drug conjugates (RDCs) with enhanced pharmacokinetics and druggability

Chong Liu, Kai liLi, Jinlei, Junhao Wang, Xinju Gao, Zengyan Mu, Lili Shi, Paul H. Song, Gang Qin

Cancer Res (2024) 84 (6_Supplement): 6032.

https://doi.org/10.1158/1538-7445.AM2024-6032

Published: 22 March 2024

View articletitled, Abstract 6032: A novel “add-on” nanobody with an albumin-binding moiety based on the intelligent ligase-dependent conjugation (iLDC) technology: An innovative and versatile approach for next-generation radionuclide drug conjugates (RDCs) with enhanced pharmacokinetics and druggability

Journal Articles

Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor

Lina Wang, Meijun Xiong, Xinju Gao, Chengang Zhou, Yu Han, Yanchun Li, Junhao Wang, Lili Shi, Gang Qin, Paul H. Song

Cancer Res (2024) 84 (6_Supplement): 2114.

https://doi.org/10.1158/1538-7445.AM2024-2114

Published: 22 March 2024

View articletitled, Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor

Journal Articles

Abstract 7168: PBI-410 (GQ1010), A novel Trop-2-targeted ADC demonstrates a favorable safety and toxicokinetic profile in multiple preclinical assessments

Yajun Sun, Vijayapal Reddy, Palaniappan Kulanthaivel, Yanwen Feng, Jie Zhao, Zhiyan Chi, Junhao Wang, Lili Shi, Gang Qin, Paul H. Song

Cancer Res (2024) 84 (6_Supplement): 7168.

https://doi.org/10.1158/1538-7445.AM2024-7168

Published: 22 March 2024

View articletitled, Abstract 7168: PBI-410 (GQ1010), A novel Trop-2-targeted ADC demonstrates a favorable safety and toxicokinetic profile in multiple preclinical assessments

Journal Articles

Abstract 2124: Validation of the intelligent glycotransferase-dependent conjugation (iGDC) platform: A groundbreaking approach for next-generation HER2-targeting ADC GQ1012 with enhanced druggability, potency, and safety

Meijun Xiong, Zengyan Mu, Meiling Xu, Chong Liu, Bo Dai, Junhao Wang, Xinju Gao, Lili Shi, Paul H. Song, Gang Qin

Cancer Res (2024) 84 (6_Supplement): 2124.

https://doi.org/10.1158/1538-7445.AM2024-2124

Published: 22 March 2024

View articletitled, Abstract 2124: Validation of the intelligent glycotransferase-dependent conjugation (iGDC) platform: A groundbreaking approach for next-generation HER2-targeting ADC GQ1012 with enhanced druggability, potency, and safety

Journal Articles

Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study

Charlotte Lemech, Chenfei Zhou, Xianbao Zhan, Yan Shi, Jieqiong Liu, Sarina A Piha-Paul, Gary Richardson, Gang Qin, Paul H. Song, Lili Shi, Yajun Sun, Yi Xia

Cancer Res (2023) 83 (8_Supplement): CT178.

https://doi.org/10.1158/1538-7445.AM2023-CT178

Published: 14 April 2023

View articletitled, Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study

Journal Articles

Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency

Lei Huang, Lili Shi, Yajun Sun, Cao Lv, Chengcheng Gong, Chong Liu, Jun Yang, Lu Jiang, Jinduo Yuan, Xuesong Li, Mingyu Hu, Xinju Gao, Yu Si, Hui Yang, Yan Shi, Bo Yang, Paul H. Song, Gang Qin, Biyun Wang

Cancer Res (2023) 83 (7_Supplement): 2702.

https://doi.org/10.1158/1538-7445.AM2023-2702

Published: 04 April 2023

View articletitled, Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency

Journal Articles

Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo

Meijun Xiong, Beibei Fan, Xinju Gao, Yajun Sun, Cao Lv, Yu Si, Xiao Liu, Lili Shi, Paul H. Song, Gang Qin

Cancer Res (2023) 83 (7_Supplement): 2640.

https://doi.org/10.1158/1538-7445.AM2023-2640

Published: 04 April 2023

View articletitled, Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo

Journal Articles

Abstract 1549: Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors

Yajun Sun, Mingyu Hu, Cao Lv, Yu Si, Xiao Liu, Xinju Gao, Dong Yang, Guangming Chen, Boyu Zhong, Tony Zhang, Lili Shi, Gang Qin, Paul H. Song

Cancer Res (2023) 83 (7_Supplement): 1549.

https://doi.org/10.1158/1538-7445.AM2023-1549

Published: 04 April 2023

View articletitled, Abstract 1549: Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors

Journal Articles

MET Signaling Regulates Glioblastoma Stem Cells

Kyeung Min Joo, Juyoun Jin, Eunhee Kim, Kang Ho Kim, Yonghyun Kim, Bong Gu Kang, Youn-Jung Kang, Justin D. Lathia, Kwang Ho Cheong, Paul H. Song, Hyunggee Kim, Ho Jun Seol, Doo-Sik Kong, Jung-Il Lee, Jeremy N. Rich, Jeongwu Lee, Do-Hyun Nam

Cancer Res (2012) 72 (15): 3828–3838.

https://doi.org/10.1158/0008-5472.CAN-11-3760

Published: 31 July 2012

View articletitled, MET Signaling Regulates Glioblastoma Stem Cells

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Abstract 347: Novel EGFR x cMET bispecific ADC GQ1033 and DLL3-ADC GQ1030 demonstrated promising therapeutic efficacy in preclinical studies

Abstract 4332: Concomitant therapy leveraging antibody-pan-KRAS^mt siRNA conjugate for PDAC and LUAD harboring KRAS mutations

Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor against diverse FGFR3 overexpression or alteration

Abstract 6032: A novel “add-on” nanobody with an albumin-binding moiety based on the intelligent ligase-dependent conjugation (iLDC) technology: An innovative and versatile approach for next-generation radionuclide drug conjugates (RDCs) with enhanced pharmacokinetics and druggability

Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor

Abstract 7168: PBI-410 (GQ1010), A novel Trop-2-targeted ADC demonstrates a favorable safety and toxicokinetic profile in multiple preclinical assessments

Abstract 2124: Validation of the intelligent glycotransferase-dependent conjugation (iGDC) platform: A groundbreaking approach for next-generation HER2-targeting ADC GQ1012 with enhanced druggability, potency, and safety

Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study

Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency

Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo

Abstract 1549: Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors

MET Signaling Regulates Glioblastoma Stem Cells

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only